Peer Review reports
From: Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus
| Original Submission | ||
|---|---|---|
| 17 Mar 2020 | Submitted | Original manuscript |
| 8 Apr 2020 | Reviewed | Reviewer Report |
| 20 Apr 2020 | Reviewed | Reviewer Report - Vinod Balasubramaniam |
| 21 May 2020 | Author responded | Author comments - Jie Yuan |
| Resubmission - Version 2 | ||
| 21 May 2020 | Submitted | Manuscript version 2 |
| 30 May 2020 | Reviewed | Reviewer Report - Vinod Balasubramaniam |
| 5 Jun 2020 | Reviewed | Reviewer Report |
| 9 Jun 2020 | Author responded | Author comments - Jie Yuan |
| Resubmission - Version 3 | ||
| 9 Jun 2020 | Submitted | Manuscript version 3 |
| Publishing | ||
| 11 Jun 2020 | Editorially accepted | |
| 31 Jul 2020 | Article published | 10.1186/s12916-020-01663-1 |
You can find further information about peer review here.